“Biosimilars are such an underutilized entity to truly drive down costs and generate savings. We are heartened by the fact that several pieces of legislation have been introduced to help change provider and patient incentives,” said Molly Burich, MS, Director, Public Policy, Biosimilars and Reimbursement at Boehringer Ingelheim. A panel at last week’s GRx+Biosims meeting … Continue reading Will Government Action to Spur the Biosimilars Industry Have Any Bite? →